

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application. The amendments made herein are made without prejudice or disclaimer.

Listing of Claims:

1. -10. (Canceled)

11. (Currently amended) A test kit for use in detecting the presence of a mammalian CC-chemokine receptor 2 in a biological sample, the test kit comprising:

a) an antibody or antigen-binding fragment thereof which binds to the amino terminal domain of a mammalian CC-chemokine receptor 2, wherein said antibody or antigen-binding fragment thereof inhibits binding of a ~~ligand~~ chemokine to the receptor and inhibits one or more functions associated with binding of said chemokine to said receptor; and

b) ~~one or more~~ or more ancillary reagents suitable for detecting the presence of a complex between said antibody or antigen-binding fragment thereof and said mammalian CC-chemokine receptor 2 or a portion thereof.

12.-44. (Canceled)

45. (Previously presented) The kit according to Claim 11, wherein said antibody or antigen-binding fragment thereof binds to a human CC-chemokine receptor 2.

46. (Canceled)

47. (Currently amended) The kit according to Claim 46, wherein the chemokine is selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP4 MCP-4 and combinations thereof.

48. (Previously presented) The kit according to Claim 11, wherein said antibody or antigen-binding fragment thereof is a monoclonal antibody or fragment thereof.

49. (Previously presented) The kit according to Claim 11, wherein said antibody or antigen-binding fragment thereof is a human antibody or fragment thereof

50. (Currently amended) The kit according to Claim 11, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab Fab' fragment and an F(ab')₂ fragment.

51 . (Previously presented) The kit according to Claim 11, wherein said antibody or antigen-binding fragment thereof is a humanized antibody or fragment thereof.

52. (Previously presented) The kit according to Claim 11, wherein said antibody or antigen-binding fragment thereof is a recombinant antibody or fragment thereof.

53. -56. (Cancel)

57. (Previously presented) The kit according to Claim 11, wherein the antibody or antigen-binding fragment thereof is lyophilized.

58. (Previously presented) The kit according to Claim 57, further comprising an acceptable diluent, excipient or carrier.

59. (Cancel)

60. (New) The kit according to Claim 11, wherein the antibody or antigen-binding fragment thereof is labeled.